安图生物
(603658)
| 流通市值：232.93亿 | | | 总市值：232.93亿 |
| 流通股本：5.81亿 | | | 总股本：5.81亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,380,035,059.48 | 2,207,103,914.63 | 1,089,195,256.05 | 4,443,655,727.69 |
| 营业收入 | 3,380,035,059.48 | 2,207,103,914.63 | 1,089,195,256.05 | 4,443,655,727.69 |
| 二、营业总成本 | 2,408,355,902.26 | 1,583,246,923.9 | 777,943,233.44 | 3,214,959,512.36 |
| 营业成本 | 1,153,825,249.86 | 764,394,036.83 | 386,453,063.84 | 1,552,245,154.49 |
| 税金及附加 | 35,859,085.1 | 21,798,912.94 | 10,900,737.72 | 50,727,338.55 |
| 销售费用 | 551,539,143.37 | 368,582,706.27 | 180,832,585.13 | 763,333,422.86 |
| 管理费用 | 148,095,505.61 | 91,426,520.73 | 46,553,519.32 | 183,734,754.8 |
| 研发费用 | 511,265,272.32 | 333,232,807.55 | 151,149,747.29 | 656,130,426.05 |
| 财务费用 | 7,771,646 | 3,811,939.58 | 2,053,580.14 | 8,788,415.61 |
| 其中:利息费用 | 16,950,785.02 | 11,625,874.44 | 6,347,252.8 | 24,541,986.54 |
| 其中:利息收入 | 10,878,628.18 | 9,302,802.12 | 5,150,017.57 | 15,381,295.46 |
| 加:公允价值变动收益 | 10,703,146.14 | 7,035,162.86 | 3,407,049.84 | 579,888.51 |
| 加:投资收益 | 58,946,984.29 | 38,094,731.87 | 22,967,999.31 | 129,381,351.61 |
| 资产处置收益 | -1,168,868.83 | 1,334.78 | 135.13 | -137,779.8 |
| 资产减值损失(新) | -7,026,352.72 | -7,323,484.6 | 1,374,245.66 | -32,691,713.54 |
| 信用减值损失(新) | -34,952,874.19 | -15,665,898.88 | -474,196.5 | -22,643,567.95 |
| 其他收益 | 65,920,794.8 | 43,101,208.78 | 25,457,104.09 | 62,563,558.61 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,064,101,986.71 | 689,100,045.54 | 363,984,360.14 | 1,365,747,952.77 |
| 加:营业外收入 | 4,151,257.69 | 3,023,712.48 | 1,544,422.67 | 3,190,228.03 |
| 减:营业外支出 | 13,977,192.9 | 4,938,201.76 | 3,716,320.19 | 6,394,267.64 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,054,276,051.5 | 687,185,556.26 | 361,812,462.62 | 1,362,543,913.16 |
| 减:所得税费用 | 84,843,418.23 | 60,208,317.18 | 33,112,994.33 | 138,413,224.5 |
| 六、净利润 | 969,432,633.28 | 626,977,239.08 | 328,699,468.29 | 1,224,130,688.66 |
| 持续经营净利润 | 969,432,633.28 | 626,977,239.08 | 328,699,468.29 | 1,224,130,688.66 |
| 归属于母公司股东的净利润 | 956,174,546.82 | 619,513,343.19 | 324,212,004.34 | 1,217,438,887.27 |
| 少数股东损益 | 13,258,086.46 | 7,463,895.89 | 4,487,463.95 | 6,691,801.39 |
| (一)基本每股收益 | 1.65 | 1.09 | 0.56 | 2.1 |
| (二)稀释每股收益 | 1.65 | 1.09 | 0.56 | 2.1 |
| 八、其他综合收益 | -138,346.28 | 70,245.37 | 13,321.47 | 424,846.11 |
| 归属于母公司股东的其他综合收益 | -138,346.28 | 70,245.37 | 13,321.47 | 424,846.11 |
| 九、综合收益总额 | 969,294,287 | 627,047,484.45 | 328,712,789.76 | 1,224,555,534.77 |
| 归属于母公司股东的综合收益总额 | 956,036,200.54 | 619,583,588.56 | 324,225,325.81 | 1,217,863,733.38 |
| 归属于少数股东的综合收益总额 | 13,258,086.46 | 7,463,895.89 | 4,487,463.95 | 6,691,801.39 |
| 公告日期 | 2024-10-26 | 2024-08-21 | 2024-04-19 | 2024-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |